Merck Loses Injunction Bid In Generic Diabetes Drug Suit

Law360, New York (April 5, 2013, 6:26 PM EDT) -- An Indian court on Friday rejected Merck Sharp & Dohme Corp.'s request for a preliminary injunction in its patent suit over Glenmark Pharmaceuticals Ltd.'s generic version of Merck's diabetes drugs Januvia and Janumet.

Merck filed suit Monday, the same day India's Supreme Court drew attention to the country's favorable treatment of generic drugs when it denied patent patent protection for an updated version of a Novartis AG cancer drug. In the instant case, Justice Rajiv Sahai Endlaw of the High Court of Delhi ruled that Merck...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.